Status:
RECRUITING
The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function
Lead Sponsor:
University of Copenhagen
Collaborating Sponsors:
Gentofte Hospital, Denmark
Conditions:
Incretin Effect
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This project will characterize the physiological effect of the hormones, GIP-, GLP-1- and GLP-2 infusions in a group of individuals that are carriers of GIP-, GLP-1- and GLP-2 receptor gene variants, ...
Detailed Description
Participants with mutations in their GLP-1- and GIP receptor will attend five randomized experimental days, A1, A2, B, C and D. On day A1 an oral glucose tolerance test (OGTT) will be performed, and o...
Eligibility Criteria
Inclusion
- BMI 19-35 kg/m2
Exclusion
- Treatment with medication or supplements that can not be discontinued for 12 hours
- \>10 objects of alcohol weekly or abuse of narcotics
- Liver disease (defined as ALAT and/or ASAT ≥ 2 x normal levels)
- Decreased kidney function (creatine levels over reference interval)
- Uncontrollable increased blood pressure (\> 140/90 mmHg)
- Low blood percentage (hemoglobin \< 8.3 mmol/l)
- Special diet or planned weight change during trial period
- Other conditions that could be expected to affect the primary or secondary outcomes
Key Trial Info
Start Date :
January 4 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06194955
Start Date
January 4 2023
End Date
December 1 2027
Last Update
May 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Denmark, 2900